WEKO3
アイテム
Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy
http://hdl.handle.net/10069/00041597
http://hdl.handle.net/10069/00041597081f60bb-1840-4d79-9562-c08bd3ffe651
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
CCA532_84.pdf (269.8 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-06-23 | |||||
| タイトル | ||||||
| タイトル | Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Immune complex antigen | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Immune complexome analysis | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Non-small-cell lung cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Nivolumab | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Therapeutic predictive biomarker | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Aizawa, Rika
× Aizawa, Rika× Nakamura, Yoichi× Ikeda, Takaya× Aibara, Nozomi× Kutsuna, Yuki J.× Kurosaki, Tomoaki× Aki, Keisei× Junya, Hashizume× Nakagawa, Hiroo× Sato, Kayoko× Kodama, Yukinobu× Nakashima, Mihoko N.× Nakashima, Mikiro× Mukae, Hiroshi× Ohyama, Kaname |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: Immune checkpoint inhibitors (ICIs) have achieved important outcomes in cancer treatment. However, current clinical biomarker tests are not suitable for some patients because they require tumor tissues and have poor predictive value for treatment responses. Therefore, the identification of biomarkers that enable screening tests in all patients is necessary. Methods: We performed an immune complexome analysis of non-small cell lung cancer patients treated with nivolumab to comprehensively identify and compare antigens incorporated into immune complexes (IC-antigens) in serum samples from the responders (n = 15) and non-responders (n = 20). Additionally, combinations of IC-antigens characteristic to the responder group were evaluated by logistic regression analysis and receiver operating characteristics curves to examine their predictiveness for ICI treatment responses. Results: The combination of predictive biomarkers detected before treatment was profilin-1, purine nucleoside phosphorylase, alpha-enolase, and nucleoside diphosphate kinase A [p = 0.0043, odds ratio = 2.26, 95% confidence interval (CI) = 1.19–4.28, area under the curve = 0.76]. The combination of predictive biomarkers detected after treatment was peptidyl-prolyl cis-trans isomerase A, ubiquitin-like modifier-activating enzyme 1, complement component C8 beta chain, and apolipoprotein L1 (p = 0.0039, odds ratio = 2.56, 95% CI = 1.25–5.23, area under the curve = 0.77). Conclusion: Combinations of serum IC-antigens may predict the therapeutic effect of nivolumab in non-small cell lung cancer patients. |
|||||
| 書誌情報 |
Clinica Chimica Acta 巻 532, p. 84-88, 発行日 2022-06-01 |
|||||
| 出版者 | ||||||
| 出版者 | Elsevier B.V. | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 00098981 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1016/j.cca.2022.05.021 | |||||
| 権利 | ||||||
| 権利情報 | © 2022 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
| 引用 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Clinica Chimica Acta, 532, pp. 84-88; 2022 | |||||
